Skip to main content

Advertisement

Table 1 Baseline characteristics of study subgroups

From: Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

  Lixisenatide Placebo p value Lixisenatide Placebo p value
Low (<8 %) baseline HbA1c High (≥8 %) baseline HbA1c
N 44 33   99 103  
Age (years), mean (SD) 61.2 (9.1) 58.7 (11.3) 0.29 58.0 (10.9) 57.5 (11.3) 0.75
Female-N (%) 14 (31.8) 8 (24.2) 0.47 36 (36.4) 36 (35.0) 0.83
Duration of diabetes (years), mean (SD) 13.1 (8.0) 12.8 (10.0) 0.89 11.3 (7.3) 12.3 (7.4) 0.34
HbA1c (%), mean (SD) 7.53 (0.29) 7.52 (0.29) 0.86 8.88 (0.62) 8.90 (0.58) 0.81
  1. SD standard deviation; BMI body mass index
  Low (<25 kg/m2) baseline BMI High (≥25 kg/m2) baseline BMI
N 77 73   66 63  
Age (years), mean (SD) 60.9 (8.9) 59.8 (10.9) 0.49 56.7 (11.7) 55.4 (11.4) 0.53
Female-N (%) 21 (27.3) 24 (32.9) 0.45 29 (43.9) 20 (31.8) 0.15
Duration of diabetes (years), mean, (SD) 12.4 (7.5) 14.1 (9.1) 0.22 11.2 (7.5) 10.5 (6.2) 0.56
HbA1c (%), mean (SD) 8.38 (0.81) 8.41 (0.73) 0.79 8.56 (0.84) 8.74 (0.84) 0.23
  1. SD standard deviation; BMI body mass index
  Short (<10 years) duration of diabetes Long (≥10 years) duration of diabetes
N 68 59   75 77  
Age (years), mean (SD) 55.9 (11.3) 53.3 (10.4) 0.19 61.8 (8.9) 61.2 (10.8) 0.71
Female-N (%) 27 (39.7) 16 (27.1) 0.13 23 (30.7) 28 (36.4) 0.46
Duration of diabetes (years), mean (SD) 5.5 (2.8) 5.9 (2.2) 0.42 17.7 (5.5) 17.5 (7.2) 0.86
HbA1c (%), mean (SD) 8.52 (0.81) 8.64 (0.86) 0.43 8.41 (0.84) 8.50 (0.74) 0.46
  1. SD standard deviation; BMI body mass index
  <65 years of age ≥65 years of age
N 97 97   46 39  
Age (years), mean (SD) 53.9 (8.6) 52.6 (8.8) 0.30 69.7 (3.9) 70.7 (4.2) 0.25
Female-N (%) 35 (36.1) 30 (30.9) 0.45 15 (32.6) 14 (35.9) 0.75
Duration of diabetes (years), mean, (SD) 10.4 (6.9) 10.5 (6.5) 0.92 14.9 (8.0) 17.2 (9.6) 0.24
HbA1c (%), mean (SD) 8.56 (0.83) 8.82 (0.78) 0.16 8.24 (0.87) 8.44 (0.74) 0.25
  1. SD standard deviation; BMI body mass index